Essential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational level
Open Access
- 28 April 2023
- journal article
- research article
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 35 (6) , 357-363
Abstract
Background: The burden of cardiovascular diseases (CVDs) and response to health systems vary widely at the subnational level in India. Our study aimed to assess the variation in state-level access to medicines for CVDs by comparing the essential medicines lists (EMLs) at the national and subnational levels in India and by rapid appraisal of the existing policies and processes of drug procurement. Methods: We assessed the inclusion of six classes of medicines for CVDs in the recent and publicly available national and subnational EMLs from July to September 2018 in the states of Telangana and Madhya Pradesh. We examined the drug procurement and distribution policies and processes using documentary review and five key informant interviews between March and June 2018. Results: The WHO’s EML, India’s national EML, and 21 of 28 publicly available (75%) Indian state and Union Territory EMLs included all six classes of essential medicines for CVDs. However, some medicines were not included in the policy packages of essential medicines meant for primary health centres. Both the states used centralized tendering and decentralized distribution as part of the public sector drug procurement process. The requirement was based on the previous year’s consumption. The approximate time between procurement planning and distribution was 7–8 months in both the states. Conclusion: Substantial variation exists in the selection of drugs for CVDs in EMLs at the subnational level in India. Improving forecasting techniques for requirement of medicines and reducing time lags between forecasting and distribution to health facilities may allow for better access to essential medicines.Keywords
This publication has 21 references indexed in Scilit:
- Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysisJournal of Pharmaceutical Policy and Practice, 2016
- Cardiovascular Diseases in IndiaCirculation, 2016
- Health systems research for policy change: lessons from the implementation of rapid assessment protocols for diabetes in low- and middle-income settingsHealth Research Policy and Systems, 2015
- Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approachBMC Health Services Research, 2015
- Hypertension in IndiaJournal Of Hypertension, 2014
- Understanding public drug procurement in India: a comparative qualitative study of five Indian statesBMJ Open, 2013
- Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological surveyThe Lancet, 2011
- Navigating the health system: diabetes care in GeorgiaHealth Policy and Planning, 2008
- Inventory management with variable lead-time dependent procurement costOmega, 2008
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesBulletin of the World Health Organization, 2007